Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × GSK2141795 × Clear all

NCT01964924 2019-09-20

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Phase 2 Completed

37 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms